bacillary meningitis, is well recognised. However, strongyloidiasis was not suspected in our patient, and diagnostic tests for this pathogen were not performed.

Katherine GC Ong<sup>1</sup>
John R Dyer<sup>2</sup>
Dickon Havne<sup>3</sup>

1 Fiona Stanley Hospital, Perth, WA. 2 Fiona Stanley Fremantle Hospital Group, South Metropolitan Health Service, Perth, WA. 3 University of Western Australia, Perth, WA.

## dickon.hayne@uwa.edu.au

Competing interests: No relevant disclosures.

doi: 10.5694/mja2.52540

© 2024 AMPCo Pty Ltd.

IN REPLY: We thank Bowyer and Prentice for their input<sup>1</sup> regarding our article<sup>2</sup> on this interesting and complex topic.

We agree with the definition of emphysematous pyelonephritis and emphysematous cystitis as described by Bowyer and Prentice. There was indeed gas evident within our patient's left renal collecting system, as shown on a computed tomography scan, which was not included in our published article as we felt that the other published images would be of more interest to readers.

We agree that sodium–glucose cotransporter type 2 (SGLT2) inhibitors cause glycosuria and have been implicated in an increased risk of urinary tract infections.<sup>3,4</sup> Our patient had been taking an SGLT2 inhibitor, which was ceased during his first admission.

The occasional association of intestinal strongyloidiasis with gram-negative sepsis and, in particular, gram-negative

- 1 Bowyer J, Prentice DA. Hypervirulent *Klebsiella* pneumoniae causing emphysematous pyelonephritis: a life-threatening pathogen within Australian communities [Letter]. *Med J Aust* 2024; 222: https://doi.org/10.5694/mja2.52541
- 2 Ong KGC, Dyer JR, Hayne D. Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life-threatening pathogen within Australian communities. Med J Aust 2024; 220: 400-402. https://www.mja.com.au/journ al/2024/220/8/hypervirulent-klebsiella-pneum oniae-causing-emphysematous-pyelonephr itis-life
- 3 Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. *Sci Rep* 2017; 7: 2824.
- 4 Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. *Diabetes Obes Metab* 2017; 19: 348-355. ■